News from Cytotheryx

Receive the Latest News from Us

Medical breakthroughs require innovative solutions, and Cytotheryx delivers. Learn more about our work from our latest news and updates.

Overview

Cytotheryx is a platform technology company solving for the limited supply of primary human hepatocytes currently used in drug discovery and disease-specific research, and supporting the development of new therapeutics for liver failure, liver disease, and rare diseases. We look forward to opportunities to share more about our work — and its benefits — with the life science community.

Contact Us

Looking for more information on our work? Get in touch with us. We’re always happy to discuss potential opportunities.

Anna Argo, Director of Business Development
Tel: +1 (877) 275 2986
Email: anna.argo@cytotheryx.com

Read Our Latest Updates

Cytotheryx, Inc. Announces Acquisition of Ambys Medicines, Inc. Intellectual Property Assets

Cytotheryx, Inc. announced today it has acquired the intellectual property assets of Ambys Medicines, Inc., which will now become part of our portfolio.

Litter Bit Better

The Cytotheryx team is committed to community volunteering. We’re proud to have spent time volunteering together to keep our city clean and beautiful.

Cytotheryx Receives 2022 BOLD Award

The Cytotheryx team is humbled and honored to have been selected as a 2022 Early Stage BOLD Award Winner at the 10th Annual BOLD Awards!

Featuring Cytotheryx in Your Work?

Reach out to us! We’re open to conversations about our work, liver disease, and how a consistent, high-quality source of primary human hepatocytes will revolutionize the biomedical field as we know it.